Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26404927.
- Also identified by DOI 10.2337/dc15-1429 and PMC identifier 4876737.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Emerging data suggest that type 1 diabetes is a more aggressive disease in children than in adults, with important differences in pathophysiology and clinical course. Therefore, the efficacy of disease-modifying therapies may be different in the two populations. Understanding the developmental and regulatory pathways for type 1 diabetes-modifying therapies in children will enable industry, academia, funders, advocacy groups, and regulators to translate new science to clinical care. This consensus report characterizes the fundamental differences in type 1 diabetes between children and adults and proposes a thoughtful approach to better understand the development and regulatory pathways for type 1 diabetes therapies.
Medical subject headings
- Diabetes Mellitus, Type 1
- Hypoglycemic Agents